- Trials with a EudraCT protocol (24)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
24 result(s) found for: Telbivudine.
Displaying page 1 of 2.
EudraCT Number: 2004-004274-87 | Sponsor Protocol Number: NV-02B-022 / CLDT600A2303 | Start Date*: 2005-09-30 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An Open Label Trial of Telbivudine (LdT) in Adults with Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies | |||||||||||||
Medical condition: chronic hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) ES (Completed) CZ (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004825-17 | Sponsor Protocol Number: preTopic17 | Start Date*: 2017-12-06 |
Sponsor Name:Charité Universitätsmedizin Berlin | ||
Full Title: A Proof-of-concept study to investigate the Efficacy of Telbivudine Over Placebo in patients with Parvovirus-associated Inflammatory Cardiomyopathy | ||
Medical condition: Parvovirus B19-induced inflammatory cardiomyopathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-004003-18 | Sponsor Protocol Number: CLDT600A2406 | Start Date*: 2006-11-16 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, open-label, controlled, mutli-center two-year study comparing efficacy and safety of telbivudine 600mg PO in combination with peg alpha-2a 180 µg with peg alpha-2a montherapy, and wit... | |||||||||||||
Medical condition: Treatment of naïve patients with HBeAg-positive compensated chronic hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) FR (Prematurely Ended) IT (Completed) DE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-003754-26 | Sponsor Protocol Number: NV-02B-019 | Start Date*: 2005-05-25 |
Sponsor Name:Idenix Pharmaceuticals, Inc. | ||
Full Title: A Randomized Trial of Switching Antiviral Therapy from Lamivudine to Telbivudine (LdT) vs. Continued Lamivudine Treatment in Adults with Chronic Hepatitis B | ||
Medical condition: chronic hepatitis B | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-000443-17 | Sponsor Protocol Number: NV-02B-011 | Start Date*: 2004-09-26 |
Sponsor Name:Idenix Pharmaceuticals, Inc. | ||
Full Title: A Randomized, Double-Blind Trial of Telbivudine (LdT) versus Lamivudine in Adults with Decompensated Chronic Hepatitis B and Evidence of Cirrhosis | ||
Medical condition: Decompensated Chronic Hepatitis B and Evidence of Cirrhosis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) LV (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-001444-20 | Sponsor Protocol Number: CLDT600ACN03 | Start Date*: 2016-05-18 | |||||||||||
Sponsor Name:Beijing Novartis Pharma Co., Ltd. | |||||||||||||
Full Title: An Open-label, Single-arm, Multicenter, Phase IV, 52-week Study to Evaluate the Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients with Chronic Hepatitis B | |||||||||||||
Medical condition: chronic hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022627-29 | Sponsor Protocol Number: IIR-HBV-2010 | Start Date*: 2011-03-29 | |||||||||||
Sponsor Name:OSPEDALE POLICLINICO S. MATTEO | |||||||||||||
Full Title: Innate immune responses in patients with chronic hepatitis B treated with Sebivo (telbivudine) | |||||||||||||
Medical condition: Chronic HBV | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000180-13 | Sponsor Protocol Number: CLDT600A2409 | Start Date*: 2011-02-03 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: OPTIMA: A Randomized, Open-label, 104-week Treatment Study to Evaluate the Efficacy and Safety of Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Road... | |||||||||||||
Medical condition: Treatment in HBeAg-negative chronic hepatitis B patients | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) ES (Completed) DE (Completed) GR (Completed) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004942-14 | Sponsor Protocol Number: CLDT600A2306 | Start Date*: 2014-05-09 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, 104-weeks treatment study to evaluate the efficacy, safety, tolerability and pharmacokinetics of telbivudine oral solution and tablets in children and adolescents with c... | |||||||||||||
Medical condition: compensated HBeAg-positive and negative chronic hepatitis B virus infection | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) GR (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006218-40 | Sponsor Protocol Number: CLDT600A2104 | Start Date*: 2008-09-02 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Telbivudine (LdT) in Children and Adolescents with Chronic Hepatitis B Virus Infection | |||||||||||||
Medical condition: Chronic hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) BG (Prematurely Ended) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002812-10 | Sponsor Protocol Number: PADD-ON | Start Date*: 2012-01-03 | |||||||||||
Sponsor Name:University Medical Center of the Johannes Gutenberg University Mainz | |||||||||||||
Full Title: A prospective, randomised, open-label phase IIb clinical trial assessing the effect of pegylated Interferon alfa-2a (Pegasys®) 180 µg once weekly for 48 weeks in addition to an ongoing nucelos(t)id... | |||||||||||||
Medical condition: Patients with chronic HBeAg-negative hepatitis B with a stable oral antiviral treatment (not containing telbivudine) and a fully suppressed viral load for at least 12 months (below limit of detecti... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001647-12 | Sponsor Protocol Number: ARB-001467-003 | Start Date*: 2018-02-06 | |||||||||||
Sponsor Name:Arbutus Biopharma Corporation | |||||||||||||
Full Title: A Phase 2a, Open-Label, Study Evaluating the Safety and Anti-Viral Activity of ARB-001467 in Non-Cirrhotic, HBeAg-Negative Subjects with Chronic HBV Infection (Genotype A or B) in Combination with ... | |||||||||||||
Medical condition: Hepatitis B virus e-antigen (HBeAg)-negative subjects with chronic hepatitis B virus infection (CHB) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004845-14 | Sponsor Protocol Number: CLDT600A2410 | Start Date*: 2008-03-12 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A single-arm, multinational, two year study evaluating the efficacy and safety of lead-in telbivudine for 24 weeks with or without tenofovir treatment intensification in adult patients with HBeAg-p... | |||||||||||||
Medical condition: Treatment of adult patients with HBeAg-positive chronic hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002010-37 | Sponsor Protocol Number: HBV1101 | Start Date*: 2012-02-17 | |||||||||||
Sponsor Name:Foundation for Liver research | |||||||||||||
Full Title: A Multi-center, Randomized, Open-label study for Induction of HBsAg decline using an add-on treatment of peginterferon alfa-2a in HBeAg-negative chronic hepatitis B patients treated with nucleos(t)... | |||||||||||||
Medical condition: Chronic hepatitis B virus infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000896-17 | Sponsor Protocol Number: SBP-9200-HBV-206 | Start Date*: 2019-05-20 |
Sponsor Name:Spring Bank Pharmaceuticals, Inc. | ||
Full Title: A PHASE 2, EXPLORATORY STUDY EVALUATING THE SAFETY AND ANTIVIRAL EFFICACY OF INARIGIVIR SOPROXIL IN NON-CIRRHOTIC, HEPATITIS B e ANTIGEN NEGATIVE SUBJECTS INFECTED WITH CHRONIC HEPATITIS B VIRUS AN... | ||
Medical condition: Chronic HBV-infected, HBeAg-negative subjects, who are non-cirrhotic and meet the cohort-specific criteria. Criteria for the planned cohorts are as follows: Cohort 1 Subjects who have been on NUC t... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-004882-15 | Sponsor Protocol Number: STOP-NUC | Start Date*: 2014-10-30 | |||||||||||
Sponsor Name:Universität Leipzig | |||||||||||||
Full Title: A multicentre randomized controlled trial evaluating the rate of sustained remission and the safety when stopping nucleos(t)ide analogue treatment in non-cirrhotic HBeAg-negative chronic Hepatitis ... | |||||||||||||
Medical condition: HBeAg negative chronic Hepatitis B virus (HBV) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000080-25 | Sponsor Protocol Number: ML28262 | Start Date*: 2012-09-18 | |||||||||||
Sponsor Name:ROCHE | |||||||||||||
Full Title: A Phase IIb, Open Label, Single Arm, Multicenter Study to Evaluate the Effect of 48-weeks Peginterferon alfa-2a (PEG-IFN) Administration on Serum HBsAg in Chronic Hepatitis B, HBeAg-Negative, Genot... | |||||||||||||
Medical condition: Chronic Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015705-40 | Sponsor Protocol Number: AI463203 | Start Date*: 2010-04-08 | |||||||||||
Sponsor Name:Bristol Myers Squibb International Corporation | |||||||||||||
Full Title: Protocol AI463203: A Study of the Safety and Efficacy of Entecavir plus Tenofovir in Adults with Chronic Hepatitis B Virus Infection with Previous Nucleoside/Nucleotide Treatment Failure | |||||||||||||
Medical condition: Chronic Hepatitis B Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) IT (Completed) DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019367-11 | Sponsor Protocol Number: ANRS HB 06 | Start Date*: 2010-08-30 | |||||||||||
Sponsor Name:ANRS | |||||||||||||
Full Title: ANRS HB 06 PEGAN Essai de phase III, randomisé, multicentrique, sans insu, évaluant à S96 la perte de l’Ag HBs suite à un traitement de 48 semaines par l’interféron pégylé alpha 2a chez des patient... | |||||||||||||
Medical condition: Cette étude va évaluer la perte de l’Ag HBs lors d’un traitement par l’interféron pégylé alpha-2a pendant 48 semaines chez des patients ayant une hépatite B chronique (AgHBe négatif), et une charge... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001400-22 | Sponsor Protocol Number: GS-US-283-1059 | Start Date*: 2014-11-25 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 for the Treatment of Virally-Suppressed Subjects with Chronic Hepatitis B | |||||||||||||
Medical condition: Chronic Hepatitis B (CHB) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
